Co-led Accipiter Biosciences' $12.7M seed alongside Takeda for AI-designed de novo protein therapies.
Accipiter Biosciences designs and develops de novo protein therapies to address complex diseases
Accipiter Biosciences designs and develops de novo protein therapies to address complex diseases. Their biologics are engineered to engage multiple pathways without the limitations of traditional combination therapies.